JP2021531249A5 - - Google Patents

Info

Publication number
JP2021531249A5
JP2021531249A5 JP2020573469A JP2020573469A JP2021531249A5 JP 2021531249 A5 JP2021531249 A5 JP 2021531249A5 JP 2020573469 A JP2020573469 A JP 2020573469A JP 2020573469 A JP2020573469 A JP 2020573469A JP 2021531249 A5 JP2021531249 A5 JP 2021531249A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
pharmaceutical composition
compound according
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573469A
Other languages
English (en)
Japanese (ja)
Other versions
JP7444797B2 (ja
JP2021531249A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041283 external-priority patent/WO2020014409A1/en
Publication of JP2021531249A publication Critical patent/JP2021531249A/ja
Publication of JP2021531249A5 publication Critical patent/JP2021531249A5/ja
Priority to JP2024025112A priority Critical patent/JP2024059789A/ja
Application granted granted Critical
Publication of JP7444797B2 publication Critical patent/JP7444797B2/ja
Priority to JP2025120296A priority patent/JP2025157418A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573469A 2018-07-11 2019-07-11 老化細胞除去組成物及びその使用 Active JP7444797B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024025112A JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696486P 2018-07-11 2018-07-11
US62/696,486 2018-07-11
PCT/US2019/041283 WO2020014409A1 (en) 2018-07-11 2019-07-11 Senolytic compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024025112A Division JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021531249A JP2021531249A (ja) 2021-11-18
JP2021531249A5 true JP2021531249A5 (cg-RX-API-DMAC10.html) 2022-07-19
JP7444797B2 JP7444797B2 (ja) 2024-03-06

Family

ID=69140375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020573469A Active JP7444797B2 (ja) 2018-07-11 2019-07-11 老化細胞除去組成物及びその使用
JP2024025112A Pending JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A Pending JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024025112A Pending JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A Pending JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Country Status (9)

Country Link
US (3) US11026963B2 (cg-RX-API-DMAC10.html)
EP (1) EP3790861A4 (cg-RX-API-DMAC10.html)
JP (3) JP7444797B2 (cg-RX-API-DMAC10.html)
KR (1) KR102843318B1 (cg-RX-API-DMAC10.html)
CN (2) CN120136941A (cg-RX-API-DMAC10.html)
IL (2) IL312612A (cg-RX-API-DMAC10.html)
MX (2) MX2021000395A (cg-RX-API-DMAC10.html)
SG (1) SG11202012099VA (cg-RX-API-DMAC10.html)
WO (1) WO2020014409A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
EP4093731A1 (en) 2020-01-20 2022-11-30 Neophore Limited Isoindoline derivatives which bind to an atp binding site
IL298608A (en) * 2020-06-01 2023-01-01 Hcw Biologics Inc Methods for treating disorders related to aging
GB202008201D0 (en) * 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
WO2022020114A2 (en) 2020-07-10 2022-01-27 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
CN118475356A (zh) * 2021-09-13 2024-08-09 鲁贝多生命科学公司 糖衍生物的药物偶联物及其作为衰老细胞裂解剂的用途
US20230138729A1 (en) * 2021-09-13 2023-05-04 Rubedo Life Sciences, Inc. Coumarin Derivatives of Sugar Analogs and Uses Thereof
US11897915B2 (en) 2021-09-13 2024-02-13 Rubedo Life Sciences, Inc. Sugar derivatives and uses thereof to prepare novel senolytic agents
CN114249782B (zh) * 2022-01-05 2023-06-30 湖南大学 一种选择性破坏衰老细胞溶酶体的前药及其制备方法与应用
WO2024036961A1 (zh) * 2022-08-19 2024-02-22 北京三秀生物医药科技有限公司 一种抗衰老相关疾病的前药及其使用方法
CN118496288B (zh) * 2023-02-06 2025-01-10 中国科学院微生物研究所 一种糖基化喜树碱类化合物Gly-CPTR及其制药用途、药物或前药及制备方法
EP4687893A1 (en) * 2023-04-06 2026-02-11 Integrated Biosciences, Inc. Compounds and uses thereof
CN116688159A (zh) * 2023-06-19 2023-09-05 江西德上制药股份有限公司 一种基于mRNA技术治疗阿尔茨海默病的药物组合物及制备方法
CN116942653A (zh) * 2023-08-25 2023-10-27 徐诺药业(南京)有限公司 艾贝司他用于制备防治细胞因子风暴相关疾病药物的用途
WO2025175039A1 (en) * 2024-02-13 2025-08-21 Luxvitae Therapeutics Inc. Duocarmycin analogs and applications thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
BR0014254A (pt) 1999-09-08 2002-08-27 Sloan Kettering Inst Cancer Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
CN1257190C (zh) 2003-04-02 2006-05-24 郭全太 聚葡萄糖生产工艺
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
JP2010513326A (ja) * 2006-12-19 2010-04-30 メシルジーン インコーポレイテッド ヒストンデアセチラーゼの阻害薬及びそのプロドラッグ
RU2481332C2 (ru) * 2007-09-25 2013-05-10 Эбботт Лэборетриз Октагидропенталеновые соединения в качестве антагонистов хемокиновых рецепторов
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
WO2010014814A2 (en) * 2008-07-30 2010-02-04 Wisconsin Alumni Research Foundation Glycosylated warfarin analogs and uses thereof
BRPI1009398A2 (pt) * 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
EP2616470B1 (en) * 2010-09-13 2016-10-12 Advinus Therapeutics Limited Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
CA2859385A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
US10661633B2 (en) 2012-03-29 2020-05-26 Signify Holding B.V. Heating device
DK2890981T3 (en) 2012-08-28 2019-03-04 Univ Tuebingen Medizinische Fakultaet Senescence tracers
WO2014205244A1 (en) 2013-06-19 2014-12-24 Demaria Marco Methods for enhancing effectiveness of medical therapies
US9993472B2 (en) * 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
CN106456699B (zh) * 2014-05-05 2021-07-02 生物风险投资有限责任公司 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
CA2962922C (en) * 2014-09-29 2021-10-26 The Scripps Research Institute Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
US20180021323A1 (en) * 2015-01-22 2018-01-25 Bioventures, Llc Flip - a selective molecular target of senescent cells
JP2018508569A (ja) * 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives

Similar Documents

Publication Publication Date Title
RU2494095C2 (ru) Модифицированные миметики лизина
JP2013525318A5 (cg-RX-API-DMAC10.html)
CO5271670A1 (es) Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
JP2007519619A5 (cg-RX-API-DMAC10.html)
JPH02503312A (ja) 化学的化合物
JPS6197256A (ja) アルキルスルホンアミドフエニルアルキルアミン類
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
JP2016539140A (ja) ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
IE920404A1 (en) Compounds
JP2016501241A5 (cg-RX-API-DMAC10.html)
GB2268933A (en) Hydroxysuccinyl hydroxyamines
CZ283602B6 (cs) Pyrrolidinové deriváty, způsob jejich přípravy a léčiva tyto deriváty obsahující
AU688164B2 (en) Metalloproteinase inhibitors
JPH05506643A (ja) Ｎ―フエニル―ｎ―アセトアミドグリシンアミド類、それらの製造およびそれらを含有する薬物
US20080188565A1 (en) Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
JP2025508071A5 (cg-RX-API-DMAC10.html)
DE10006453A1 (de) Piperidylcarbonsäuren als Integrinantagonisten
JP2009040767A5 (cg-RX-API-DMAC10.html)
JP2002501039A5 (cg-RX-API-DMAC10.html)
FR2901273A1 (fr) Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
JPS6327426A (ja) 胃腸疾患処置剤フェニルエタノ−ルアミン誘導体類
JP3647451B2 (ja) ベンゾラクタム誘導体
RU2013113301A (ru) Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
JP2025505229A5 (cg-RX-API-DMAC10.html)
AP694A (en) Nitro-benzamides useful as anti-arrhythmic agents.